Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Hyatt Hotels Corporation (H) vs Eli Lilly And Co (LLY) Price & Performance

Hyatt Hotels CorporationTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Hyatt Hotels Corporation vs Eli Lilly And Co — how do they compare? Hyatt Hotels Corporation trades at $172.22 (market cap $16.03B), while Eli Lilly And Co trades at $1,214.89 (market cap $1.10T). The key difference: Eli Lilly And Co is far larger — about 68.6× Hyatt Hotels Corporation's market cap, and Eli Lilly And Co pays the higher dividend (0.56%). Which is the better fit depends on your goals.

HLLY
Market Cap
$16.03B$1.10T
Sector
Consumer CyclicalHealth
52-Week High
$202.09$1.24K
52-Week Low
$135.42$639.43
Enterprise Value
$19.93B$1.14T
Dividend Yield
0.35%0.56%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Hyatt Hotels Corporation

Hyatt Hotels Corp (H) trades at $177.71, down 0.65% on the day, with a bearish technical signal and mixed fundamentals. Recent earnings beats in Q2 2026 and a raised RevPAR outlook highlight operational momentum, but high valuation ratios and a negative net income in 2025 pose concerns. The stock is near its 52-week high of $206.86, with support at $176 and resistance at $180.

The outlook is cautious; while fee growth and travel demand support expansion, the stock's rich valuation and debt levels warrant patience. Risks include regional weakness and project delays. Analysts maintain a mixed consensus with a $201 price target, suggesting limited near-term upside amid balanced investor sentiment.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,185.71, down 0.59% on the day, with a bullish technical signal from moving averages and strong fundamental momentum. The company reported Q2 2026 revenue growth of 48% to $23 billion, beating estimates, driven by demand for Mounjaro and Zepbound. Valuation ratios like P/E of 39.8 and P/S of 13.34 reflect high growth expectations, while profitability remains robust with a net income margin of 33.53%.

Outlook is positive due to pipeline advancements like retatrutide and raised 2026 guidance, but risks include competitive pressures and regulatory scrutiny. Analysts are bullish with a consensus price target of $1,380, citing sustained double-digit growth and market leadership in weight-loss drugs as key drivers for upside.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Hyatt Hotels Corporation

Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.

Read more on H

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY